Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -3.93
- Piotroski Score 3.00
- Grade Buy
- Symbol (GBIO)
- Company Generation Bio Co.
- Price $1.31
- Changes Percentage (-2.96%)
- Change -$0.04
- Day Low $1.24
- Day High $1.38
- Year High $4.65
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/20/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.55
- Trailing P/E Ratio -1.28
- Forward P/E Ratio -1.28
- P/E Growth -1.28
- Net Income $-126,612,000
Income Statement
Quarterly
Annual
Latest News of GBIO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Companies Like Generation Bio (NASDAQ:GBIO) Are In A Position To Invest In Growth
Investors are often attracted to unprofitable companies that show potential for growth. Generation Bio, despite its cash burn rate, had a 3.4-year cash runway as of March 2024 with $219m in cash and r...
By Yahoo! Finance | 3 months ago
